Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. CanSino Biologics Inc.
  6. Summary
    6185   CNE100003F01

CANSINO BIOLOGICS INC.

(6185)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
06/10/2021 06/11/2021 06/15/2021 06/16/2021 06/17/2021 Date
335 369.8 369.8 358.4 340.4 Last
939723 2653713 1499961 1834676 5163596 Volume
-0.12% +10.39% 0.00% -3.08% -5.02% Change
Financials
Sales 2021 19 012 M 2 949 M 2 949 M
Net income 2021 5 447 M 845 M 845 M
Net cash position 2021 8 959 M 1 390 M 1 390 M
P/E ratio 2021 9,15x
Yield 2021 0,00%
Sales 2022 30 948 M 4 801 M 4 801 M
Net income 2022 13 240 M 2 054 M 2 054 M
Net cash position 2022 16 618 M 2 578 M 2 578 M
P/E ratio 2022 5,02x
Yield 2022 0,00%
Capitalization 116 B 17 930 M 17 935 M
EV / Sales 2021 5,61x
EV / Sales 2022 3,20x
Nbr of Employees 726
Free-Float 37,1%
More Financials
Company
CanSino Biologics Inc is a clinical-stage vaccine company in China. The Company's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia. 
Sector
Pharmaceuticals
Calendar
-
More about the company
Ratings of CanSino Biologics Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about CANSINO BIOLOGICS INC.
06/15CANSINO BIOLOGICS  : Brazil to buy single-shot Chinese COVID-19 vaccine
RE
06/15JOHNSON & JOHNSON  : COVID-19 Vaccine Wins Emergency Use Approval In Malaysia
MT
06/09China to study using CanSinoBIO COVID shots as a booster
RE
06/01WHO approves Sinovac COVID shot in second Chinese milestone
RE
05/31Sinopharm's Wuhan affiliate boosts COVID-19 shot annual capacity to 1 billion..
RE
05/25China's Kangtai Biological, partners agree to run Phase III trial in Chile - ..
RE
05/24CANSINO BIOLOGICS  : Bio's COVID-19 Vaccine Meets Manufacturing Standards in Hun..
MT
05/24CANSINO BIOLOGICS  : CanSinoBIO Receives European GMP Certification for its COVI..
AQ
05/22CANSINO BIOLOGICS  : CanSinoBIO Receives EU GMP Certificate
PU
05/19Brazil in vaccine talks with Moderna, reviewing CanSino shot
RE
05/18CANSINO BIOLOGICS  : Bio, Shanghai Pharma Inject $171 Million in Additional Fund..
MT
05/17CANSINO BIOLOGICS  : Discloseable transaction purchase of structured deposits
PU
05/13Inside the Hunt for a Link Between Some Covid-19 Vaccines and Rare Blood Clot..
DJ
05/12CANSINO BIOLOGICS  : Supplemental Form of Proxy for use at the 2020 Annual Gener..
PU
05/12CANSINO BIOLOGICS  : Supplemental notice of 2020 annual general meeting
PU
More news
News in other languages on CANSINO BIOLOGICS INC.
06/01L'OMS approuve le vaccin développé par le chinois Sinovac
05/28México aprueba uso "de emergencia" de vacuna contra COVID-19 de Janssen-Cilag
05/14COVID  : ricercatore tedesco dice di aver scoperto causa trombosi vaccini
05/06Las farmacéuticas caen en Bolsa ante el respaldo de Biden a exención de paten..
05/06MÄRKTE ASIEN/Tokio sehr fest - Chin. Impfstoffhersteller stürzen ab
More news
Analyst Recommendations on CANSINO BIOLOGICS INC.
More recommendations
Stock Trading Strategies
CANSINO BIOLOGICS INC. - 04/26
The underlying trend is in force again
BUY
More Stock Trading Analysis
Chart CANSINO BIOLOGICS INC.
Duration : Period :
CanSino Biologics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CANSINO BIOLOGICS INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 345,69 CNY
Last Close Price 282,69 CNY
Spread / Highest target 39,8%
Spread / Average Target 22,3%
Spread / Lowest Target -7,30%
EPS Revisions
Managers and Directors
NameTitle
Xue Feng Yu Chairman, Chief Executive Officer & GM
Jing Wang Chief Financial Officer & Board Secretary
Jiang Feng Li Chairman-Supervisory Board
Tao Zhu Executive Director, CSO & Deputy General Manager
Jun Qiang Li Senior Director-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
CANSINO BIOLOGICS INC.92.86%17 930
CSL LIMITED6.72%103 997
WUXI BIOLOGICS (CAYMAN) INC.17.51%65 667
BIOGEN INC.56.63%57 741
SAMSUNG BIOLOGICS CO.,LTD.0.85%48 638
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.20.95%44 390